MZF1 and central nervous system cancer: High expression of MZF1, HK2, or PGK1 was also associated with poor survival of patients with breast cancer, endometrial carcinoma, glioma, head and neck carcinoma, lung cancer, lymphoma, pancreatic cancer, or renal clear cell carcinoma (Figure S3).